Vaccine News and Research

Latest Vaccine News and Research

VTT receives innovation prize for technological development work behind allergy vaccine

The European Association of Research and Technology Organisations EARTO has awarded VTT Technical Research Centre of Finland an innovation prize for the technological development work behind allergy vaccine.

5 Dec 2013

Viewpoints: Why can't health website be like Amazon?; debunking GOP's resistance to Medicaid

For an "Amazon-like" experience, it isn't enough to have a website that functions on the front end, the back end and in between. ... You also need an Amazon-like culture, which is the product of other Amazon-like realities.

5 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

TB vaccine may help prevent multiple sclerosis

A vaccine used to prevent tuberculosis in other parts of the world may help prevent multiple sclerosis in people who show the beginning signs of the disease, according to a new study published in the December 4, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Dec 2013

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

MassBiologics of the University of Massachusetts Medical School has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent hepatitis C virus recurrence in patients receiving a liver transplant.

5 Dec 2013

Wrapping in low molecular weight poly can help stabilize hemoglobin

A UConn research team has found a way to stabilize hemoglobin, the oxygen carrier protein in the blood, a discovery that could lead to the development of stable vaccines and affordable artificial blood substitutes.

4 Dec 2013

1950s H2N2 avian influenza A virus still pose threat to human health

St. Jude Children's Research Hospital scientists have evidence that descendants of the H2N2 avian influenza A virus that killed millions worldwide in the 1950s still pose a threat to human health, particularly to those under 50. The research has been published in an advance online edition of the Journal of Virology.

4 Dec 2013

UCI-led study results have important implications for HIV vaccine development

Infectious disease researchers have identified a novel mechanism wherein HIV-1 may facilitate its own transmission by usurping the antibody response directed against itself. These results have important implications for HIV vaccine development and for understanding the earliest events in HIV transmission.

4 Dec 2013

Better understanding of cancer evolution could help in early detection of cancers

A new appreciation of how cancer cells evolve could help scientists design better screening methods to catch cancer before it advances.

4 Dec 2013

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

Researchers predict seasonal influenza outbreaks in 108 cities across the U.S.

Scientists were able to reliably predict the timing of the 2012-2013 influenza season up to nine weeks in advance of its peak. The first large-scale demonstration of the flu forecasting system by scientists at Columbia University's Mailman School of Public Health was carried out in 108 cities across the United States.

4 Dec 2013

Microneedle technique may provide a painless way to deliver drugs, vaccines

Microneedles on a sticking-plaster-like patch may be the painless and safe way doctors will test for drugs and some infections in the future, thanks to work supported by the Engineering and Physical Sciences Research Council (EPSRC).

3 Dec 2013

Research proves effectiveness of vaccine against leishmaniasis

The disease is considered endemic in the south states of Mexico. A research executed in the Autonomous University of Yucatan (UADY) has successfully proved, in test animals, the effectiveness of a vaccine that immunizes the organism against leishmaniasis, an ailment transmitted through insects very similar to mosquitos and mainly presents symptoms in the skin, liver or spleen.

3 Dec 2013

Researchers discover why parasite that causes deadliest form of malaria only infects humans

Researchers have discovered why the parasite that causes the deadliest form of malaria only infects humans.

3 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA-both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.

2 Dec 2013

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.

1 Dec 2013

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

Study brings effective hepatitis C cure closer to reality

Scientists at The Scripps Research Institute have determined the most detailed picture yet of a crucial part of the hepatitis C virus, which the virus uses to infect liver cells. The new data reveal unexpected structural features of this protein and should greatly speed efforts to make an effective hepatitis C vaccine.

29 Nov 2013

Scientists design small synthetic molecules capable of blocking AIDS virus replication

A multidisciplinary team of scientists from Spanish universities and research centres, among which is the University of Valencia, has managed to design small synthetic molecules capable of joining to the genetic material of the AIDS virus and blocking its replication.

28 Nov 2013